Data sharing of de-identified individual participant data is being adopted by an increasing number of sponsors of human clinical trials. In addition to standardizing data syntax for shared trial data, semantic integration of various data elements is the focus of several initiatives that define research common data elements. This perspective article, in the first part, compares several data sharing platforms for de-identified clinical research data in terms of their size, policies and supported features. In the second part, we use a case study approach to describe in greater detail one data sharing platform (Data Share from National Institute of Drug Abuse). We present data on the past use of the platform, data formats offered, data de-identification approaches and its use of research common data elements. We conclude with a summary of current and expected future trends that facilitate secondary research use of data from completed human clinical trials.
BertagnolliMMSartorOChabnerBAet al. Advantages of a truly open-access data-sharing model. N Engl J Med2017; 376: 1178–1181.
2.
RichessonRLNadkarniP. Data standards for clinical research data collection forms: current status and challenges. J Am Med Inform Assoc2011; 18: 341–346.
3.
SudlowRBransonJFriedeTet al. EFSPI/PSI working group on data sharing: accessing and working with pharmaceutical clinical trial patient level datasets—a primer for academic researchers. BMC Med Res Methodol2016; 16(Suppl. 1): 73.
4.
TaichmanDBSahniPPinborgAet al. Data sharing statements for clinical trials: a requirement of the International Committee of Medical Journal Editors. PLoS Med2017; 14: e1002315.
Clinical Data Interchange Standards Consortium (CDISC). Clinical trial registry XML (CTR-XML). Austin, TX: CDISC, 2015.
7.
U.S. National Library of Medicine. FAQ: protocol registration and results system. Bethesda, MD: U.S. National Library of Medicine, 2016.
8.
Institute of Medicine, Board on Health Sciences Policy and Committee on Strategies for Responsible Sharing of Clinical Trial Data. Concepts and methods for de-identifying clinical trial data (Appendix B). In: Sharing clinical trial data: maximizing benefits, minimizing risk. Washington, DC: National Academies Press, 2015. https://www.nap.edu/catalog/18998/sharing-clinical-trial-data-maximizing-benefits-minimizing-risk
9.
LerouxHMetke-JimenezALawleyMJ. Towards achieving semantic interoperability of clinical study data with FHIR. J Biomed Semantics2017; 8: 41.
KushRGoldmanM. Fostering responsible data sharing through standards. N Engl J Med2014; 370: 2163–2165.
12.
KaraaARahmanSLombesAet al. Common data elements for clinical research in mitochondrial disease: a National Institute for Neurological Disorders and Stroke project. J Inherit Metab Dis2017; 40: 403–414.
13.
HendershotTPanHHainesJet al. Using the PhenX Toolkit to add standard measures to a study. Curr Protoc Hum Genet2011; 86: 1.21.1–1.21.17.
SchadowGMeadCNWalkerDM. The HL7 reference information model under scrutiny. Stud Health Technol Inform2006; 124: 151–156.
16.
MahmoudSBoydACurcinVet al. The ‘PEARL’ data warehouse: initial challenges faced with semantic and syntactic interoperability. Stud Health Technol Inform2017; 235: 156–160.
17.
SheehanJHirschfeldSFosterEet al. Improving the value of clinical research through the use of common data elements. Clin Trials2016; 13: 671–676.
18.
SouzaTKushREvansJP. Global clinical data interchange standards are here!Drug Discov Today2007; 12: 174–181.
19.
PitcherBKhojaLHamiltonRJet al. Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS). PLoS ONE2017; 12: e0170544.
20.
University of Oxford e-Research Center. FAIRSharing website: listing of databases, 2017. https://fairsharing.org/databases/ Date accessed is March 7 2018
21.
HuserVCiminoJJ. Linking ClinicalTrials.gov and PubMed to track results of interventional human clinical trials. PLoS ONE2013; 8: e68409.
22.
BurtonPRMurtaghMJBoydAet al. Data Safe Havens in health research and healthcare. Bioinformatics2015; 31: 3241–3248.
23.
National Institutes of Health. Trans-NIH BioMedical Informatics Coordinating Committee. https://www.nlm.nih.gov/NIHbmic/ (2017, accessed 7 March 2018).
24.
Shmueli-BlumbergDHuLAllenCet al. The National Drug Abuse Treatment Clinical Trials Network Data Share project: website design, usage, challenges, and future directions. Clin Trials2013; 10: 977–986.
25.
WuLTPanJJBlazerDGet al. The construct and measurement equivalence of cocaine and opioid dependences: a National Drug Abuse Treatment Clinical Trials Network (CTN) study. Drug Alcohol Depend2009; 103: 114–123.
26.
WuLTBlazerDGWoodyGEet al. Alcohol and drug dependence symptom items as brief screeners for substance use disorders: results from the Clinical Trials Network. J Psychiatr Res2012; 46: 360–369.
27.
WuLTBlazerDGPatkarAAet al. Heterogeneity of stimulant dependence: a National Drug Abuse Treatment Clinical Trials Network study. Am J Addict2009; 18: 206–218.
28.
WuLTBlazerDGStitzerMLet al. Infrequent illicit methadone use among stimulant-using patients in methadone maintenance treatment programs: a National Drug Abuse Treatment Clinical Trials Network study. Am J Addict2008; 17: 304–311.
29.
WuLTPanJJBlazerDGet al. Using a latent variable approach to inform gender and racial/ethnic differences in cocaine dependence: a National Drug Abuse Treatment Clinical Trials Network study. J Subst Abuse Treat2010; 38(Suppl. 1): S70–S79.
30.
BrooksAMeadeCSPotterJSet al. Gender differences in the rates and correlates of HIV risk behaviors among drug abusers. Subst Use Misuse2010; 45: 2444–2469.
31.
LindbladRHuLOdenNet al. Mortality rates among substance use disorder participants in clinical trials: pooled analysis of twenty-two clinical trials within the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat2016; 70: 73–80.
32.
HartzlerBDonovanDMHuangZ. Rates and influences of alcohol use disorder comorbidity among primary stimulant misusing treatment-seekers: meta-analytic findings across eight NIDA CTN trials. Am J Drug Alcohol Abuse2011; 37: 460–471.
33.
WuLTPanJJBlazerDGet al. An item response theory modeling of alcohol and marijuana dependences: a National Drug Abuse Treatment Clinical Trials Network study. J Stud Alcohol Drugs2009; 70: 414–425.
34.
BrooksAJLokhnyginaYMeadeCSet al. Racial/ethnic differences in the rates and correlates of HIV risk behaviors among drug abusers. Am J Addict2013; 22: 136–147.
35.
McPhersonSBrooksOBarbosa-LeikerCet al. Examining longitudinal stimulant use and treatment attendance as parallel outcomes in two contingency management randomized clinical trials. J Subst Abuse Treat2016; 61: 18–25.
36.
WuLTSwartzMSPanJJet al. Evaluating brief screeners to discriminate between drug use disorders in a sample of treatment-seeking adults. Gen Hosp Psychiatry2013; 35: 74–82.
37.
HartzlerBDonovanDMHuangZ. Comparison of opiate-primary treatment seekers with and without alcohol use disorder. J Subst Abuse Treat2010; 39: 114–123.
38.
LindbladRCampanellaMStyersDet al. Strategies for safety reporting in substance abuse trials. Am J Drug Alcohol Abuse2011; 37: 440–445.
39.
CoadySAMensahGAWagnerELet al. Use of the National Heart, Lung, and Blood Institute data repository. N Engl J Med2017; 376: 1849–1858.
40.
Institute of Medicine, Board on Health Sciences Policy and Committee on Strategies for Responsible Sharing of Clinical Trial Data. Sharing clinical trial data: maximizing benefits, minimizing risk. Washington, DC: The National Academies Press, 2015, p. 304.
BiererBECrosasMPierceHH. Data authorship as an incentive to data sharing. N Engl J Med2017; 376: 1684–1687.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
